Sept 14 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP CLINICAL DEVELOPMENT UPDATE FOR ITS FIRST-IN-CLASS LAG-3 ANTIGEN PRESENTING CELL ACTIVATOR CANDIDATE EFTILAGIMOD ALPHA
- IMMUTEP LTD - NEW AND IMPORTANT CLINICAL DATA IN 1L NSCLC EXPECTED IN Q4 2022
- IMMUTEP LTD - PLANNING AND REGULATORY INTERACTIONS ONGOING WITH A FOCUS NOW PRIORITISING 1(ST) LINE (1L) NSCLC
- IMMUTEP LTD - CONTINUED EXPANSION OF EFTI IN ADDITIONAL INDICATIONS AND COMBINATIONS PLANNED
- IMMUTEP LTD - STRONG BALANCE SHEET PROVIDES CASH RUNWAY INTO EARLY 2024
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.8¢ | $362.9K | 1.448M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 42000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 271046 | 5 |
View Market Depth
| Last trade - 16.10pm 16/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |